Summary of Omnicell, Inc. (NASDAQ:OMCL) Ratings

May 17, 2018 - By Julia Grubbs

Omnicell, Inc. (NASDAQ:OMCL) Corporate Logo
Big Money Sentiment increased to 1.12 in Q4 2017. It has change of 0.10, from 2017Q3’s 1.02. The ratio increased due to Omnicell, Inc. positioning: 14 sold and 72 reduced. 27 funds acquired positions and 69 increased positions. Investors holded 37.10 million in 2017Q3 but now own 37.38 million shares or 0.77% more.
Bnp Paribas Arbitrage Sa invested 0% in Omnicell, Inc. (NASDAQ:OMCL). Juncture Wealth Strategies Ltd Liability reported 25,227 shs stake. Martin And Incorporated Tn accumulated 65,165 shs. Principal reported 0.02% of its capital in Omnicell, Inc. (NASDAQ:OMCL). Moreover, First Savings Bank Of Omaha has 0.07% invested in Omnicell, Inc. (NASDAQ:OMCL) for 25,420 shs. Mondrian Partners stated it has 60,461 shs or 0.07% of all its holdings. Snyder Management L P owns 208,885 shs or 0.5% of their US capital. Wells Fargo & Mn owns 259,293 shs. Solaris Asset Mgmt holds 0.03% or 1,200 shs. 88,153 were accumulated by Rhumbline Advisers. Kopp Inv Ltd Liability Co holds 68,841 shs or 3.34% of its capital. Champlain Investment Prtnrs Limited Liability has 0.8% invested in Omnicell, Inc. (NASDAQ:OMCL). Qs Investors Ltd Liability Corporation reported 1,247 shs. Thompson Davis & has invested 0.06% in Omnicell, Inc. (NASDAQ:OMCL). Thrivent Fin For Lutherans owns 612,780 shs for 0.1% of their capital.

Omnicell, Inc. registered $1.81 million net activity with 0 insider buys and 7 sales since December 15, 2017. On Friday, May 11 a trade for 3,456 shs valued at $164,562 was made by Kuipers Peter J.. Seim Robin Gene had sold 13,286 shs worth $617,524. JOHNSTON DAN S had sold 11,284 shs worth $507,248. LIPPS RANDALL A also sold $361,938 worth of Omnicell, Inc. (NASDAQ:OMCL) shs.

Omnicell, Inc. (NASDAQ:OMCL) Ratings Coverage

In total 4 analysts cover Omnicell (NASDAQ:OMCL). “Buy” rating has 2, “Sell” are 0, while 2 are “Hold”. 50% are bullish. 7 are the (NASDAQ:OMCL)’s analyst reports since December 5, 2017 according to StockzIntelligence Inc. The stock rating was maintained by Oppenheimer with “Buy” on Monday, January 29. On Thursday, April 26 Cantor Fitzgerald maintained Omnicell, Inc. (NASDAQ:OMCL) rating. Cantor Fitzgerald has “Buy” rating and $6300 target. On Friday, February 2 the rating was maintained by PiperJaffray with “Neutral”. On Friday, February 2 the stock of Omnicell, Inc. (NASDAQ:OMCL) earned “Hold” rating by Craig Hallum. In Tuesday, December 5 report Cantor Fitzgerald maintained it with “Buy” rating and $60.0 target. On Thursday, February 1 the company was maintained by Cantor Fitzgerald. On Tuesday, December 5 Oppenheimer maintained Omnicell, Inc. (NASDAQ:OMCL) with “Buy” rating. Listed here are Omnicell, Inc. (NASDAQ:OMCL) PTs and latest ratings.

26/04/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $63.0000 Maintain
02/02/2018 Broker: PiperJaffray Old Rating: Neutral New Rating: Neutral Old Target: $38 New Target: $44 Maintain
02/02/2018 Broker: Craig Hallum Rating: Hold Downgrade
01/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $63.0 Maintain
29/01/2018 Broker: Oppenheimer Rating: Buy New Target: $55.0 Maintain
05/12/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $60.0 Maintain
05/12/2017 Broker: Oppenheimer Rating: Buy New Target: $55.0 Maintain

OMCL is hitting $46.35 during the last trading session, after increased 0.65%.Omnicell, Inc. has volume of 224,857 shares. Since May 17, 2017 OMCL has risen 5.20% and is uptrending. The stock underperformed the S&P500 by 6.35%.

Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide.The company has $1.80 billion market cap. The firm operates through two divisions, Automation and Analytics, and Medication Adherence.87.45 is the P/E ratio. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Savvy Mobile Medication Workstation, which provides a platform for hospital information systems.

Another two news for Omnicell, Inc. (NASDAQ:OMCL) were recently posted by: Prnewswire.com on April 26, 2018 with title “Omnicell Announces First Quarter 2018 Results”. The other Seekingalpha.com‘s article was titled “Omnicell’s (OMCL) CEO Randall Lipps on Q1 2018 Results – Earnings Call Transcript” and posted on April 27, 2018.

Omnicell, Inc. (NASDAQ:OMCL) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.